Yesterday, scientists presented positive results from our Phase I clinical trial of ALN-PCS at the American Heart Association’s Arteriosclerosis, Thrombosis and Vascular Biology 2012 Scientific Sessions held in Chicago. Results showed that administration of a single dose of ALN-PCS, in the absence of concomitant lipid-lowering agents such as statins, resulted in statistically significant and durable reductions of PCSK9 plasma levels of up to 84% and lowering of LDL-C of up to 50%.
View our presentation (572 KB PDF) View our release (572 KB PDF)Posts Tagged with: Delivery
March 1, 2012
Delivery Strategies for RNAi Therapeutics
Our scientists presented an update on our RNAi delivery strategies at the AsiaTIDES conference this week. The presentation focuses on our recent progress utilizing conjugates and lipid nanoparticles for systemic adminstration of RNAi therapeutics.
View our presentation (2.4MB PDF)January 4, 2012
ALN-PCS Preliminary Phase I Clinical Results
In January 2012, we presented positive preliminary data from our ALN-PCS Phase I study at Brigham and Women’s Hospital in Boston. Data show that ALN-PCS demonstrated robust, statistically significant, and dose-dependent lowering of both PCSK9 and LDL cholesterol levels.
Read our Press Release ALN-PCS Phase I Data Presentation (3.6MB PPT) Listen to Conference CallOctober 11, 2011
New Alnylam Papers on Systemic Delivery of RNAi Therapeutics
We published two peer-reviewed papers in top-tier journals documenting the systemic delivery of RNAi therapeutics to certain immune and inflammatory cells. The findings from these studies provide us with the opportunity to explore RNAi therapeutic approaches to silence genes involved in inflammatory, autoimmune, and cardiovascular diseases, as well as certain cancers.
Read our press release Nature Biotechnology articleOctober 9, 2011
Therapeutic siRNA silencing in inflammatory monocytes in mice
July 22, 2011
Combinatorial synthesis of chemically diverse core-shell nanoparticles for intracellular delivery
June 18, 2011
Synergistic Silencing: Combinations of Lipid-like Materials for Efficacious siRNA Delivery
March 4, 2010
Alnylam RNAi Roundtable: Delivery
In March 2010, we hosted an RNAi Roundtable where Alnylam’s Dr. Akin Akinc, Associate Director of Research, provided an update on the latest advances around the delivery of RNAi therapeutics.
Delivery RNAi Roundtable webcast, March 2010 (64.4 MB MP3) Delivery RNAi Roundtable, March 2010 (3.2 MB PPT)